New drug combo shows promise for Tough-to-Treat bladder cancer

NCT ID NCT04963153

First seen Nov 01, 2025 · Last updated Apr 26, 2026 · Updated 26 times

Summary

This early-phase trial tests a combination of two drugs—erdafitinib and enfortumab vedotin—for people with advanced bladder cancer that has spread and has specific changes in the FGFR2/3 genes. The study includes about 24 adults whose cancer worsened after standard chemotherapy. The goal is to find the safest and most effective dose and see if the combination can shrink or stabilize the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah, 84112, United States

  • Los Angeles General Medical Center

    Los Angeles, California, 90033, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • NYP/Weill Cornell Medical Center

    New York, New York, 10065, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • UCHealth University of Colorado Hospital

    Aurora, Colorado, 80045, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas, 75390, United States

  • University Health Network-Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

Conditions

Explore the condition pages connected to this study.